492% in 1 hour from $0.42 to $2.49HUGE 🚀 +492% from $0.42 to $2.49 in 1 hour 🔥 NASDAQ:MBRX from halt to halt moves so wild the exchange had to pause trading to cool off a bit
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−7.12 USD
−21.76 M USD
0.00 USD
14.01 M
About Moleculin Biotech, Inc.
Sector
Industry
CEO
Walter V. Klemp
Website
Headquarters
Houston
Founded
2015
FIGI
BBG00JVRFDT8
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe in July 2015 and is headquartered in Houston, TX.
MBRX Annamycin Fast Track and Orphan Drug Designation from FDAMoleculin Biotech`s Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma lung metastases.
the FDA agreed with Moleculin Biotech`s Investigational New Drug (IND) application to study WP1122 for the treatment of Glioblastoma Multiforme (GBM) to
Idea for next weeks, buy Possible Entry to make some money .
Volume is picking up.
Low float.
Support bounce, 2.06
Ressist 2.6
Position started 2.08
$MBRX Moleculin biotech $MBRX seems to have grit for sellThe Marketmiracle advisor reported last night a major entry on the stock $MBRX with a potential profit of 300% approximately
The company Moleculin Biotech has several active trials all in the field of cancer research and recently also against covid, has recently presented quarterly and annual data
MBRX - 100% Spike coming soon?I think that $3 is the honey spot here. If it goes this low there will likely be a nice 100% gain. It will likely drop to some degree then make up for it in the short term.
100% Survival Achieved in Osteosarcoma Lung MetastasesMoleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model
a preclinical study in animals demonstrated a potentially significant therapeutic benefit of Annamycin against metastatic osteosarcoma.
Computerized tomography (CT) scans demonstrated that animals treated with
$MBRX (fm @Marcoux)Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.
$MBRX Potential Break Above 200ma Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the
Moleculin Announces Positive Interim Results in Pediatric Brain MBRX: Moleculin Biotech, Inc.
2020-10-01 07:30:00
Moleculin Announces Positive Interim Results in Pediatric Brain Tumor Phase 1 Clinical Trial at Emory University
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of 0K2H is 1.02 USD — it has decreased by −2.38% in the past 24 hours. Watch MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) stocks are traded under the ticker 0K2H.
0K2H stock has risen by 6.17% compared to the previous week, the month change is a −1.44% fall, over the last year MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) has showed a −79.10% decrease.
We've gathered analysts' opinions on MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) future price: according to them, 0K2H price has a max estimate of 20.00 USD and a min estimate of 4.00 USD. Watch 0K2H chart and read a more detailed MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) stock forecast: see what analysts think of MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) and suggest that you do with its stocks.
0K2H reached its all-time high on Feb 16, 2018 with the price of 3,780.00 USD, and its all-time low was 0.47 USD and was reached on Feb 12, 2025. View more price dynamics on 0K2H chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
0K2H stock is 3.90% volatile and has beta coefficient of 3.08. Track MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) stock price on the chart and check out the list of the most volatile stocks — is MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) there?
Today MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) has the market capitalization of 13.94 M, it has decreased by −6.04% over the last week.
Yes, you can track MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) financials in yearly and quarterly reports right on TradingView.
MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
0K2H earnings for the last quarter are 0.25 USD per share, whereas the estimation was −1.28 USD resulting in a 119.48% surprise. The estimated earnings for the next quarter are −0.56 USD per share. See more details about MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) earnings.
MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
0K2H net income for the last quarter is −1.88 M USD, while the quarter before that showed −10.59 M USD of net income which accounts for 82.23% change. Track more MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) financial stats to get the full picture.
No, 0K2H doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 30, 2025, the company has 17 employees. See our rating of the largest employees — is MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) on this list?
Like other stocks, 0K2H shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) stock shows the sell signal. See more of MOLECULIN BIOTECH INC COM USD0.001(POST REV SPLIT) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.